Pharmafile Logo

T-DM1

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

- PMLiVE

J&J partner drive nets 15 new deals, and another NASH drug

Fosters new collaborations in treatment-resistant depression, infectious diseases and cancer

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Bayer symbol

Bayer nets speedy US review for regorafenib in liver cancer

Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales

Roche Basel Switzerland

Roche’s haemophilia A drug hits targets in registration trial

Emicizumab from Japanese affiliate Chugai cleared a phase III trial

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Roche Basel Switzerland

Genentech names Anderson new CEO as Ian Clark retires

Leadership changes come as the Roche subsidiary faces increasing biologics competition

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

- PMLiVE

NICE U-turn sees Celgene’s Imnovid backed for multiple myeloma

New data and a discount swayed the cost-effectiveness body

- PMLiVE

EU citizens are living longer, but not always in good health

Report finds huge inequalities between and within countries despite higher life expectancy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links